The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / News Updates for Diclofenac Sodium, Denosumab & Sarilumab

News Updates for Diclofenac Sodium, Denosumab & Sarilumab

June 20, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

When taking sarilumab, there is an increased risk of the development of serious infections that may lead to hospitalization or death. In clinical trials, the most common adverse reactions were neutropenia (7–10%), increased alanine aminotransferase levels (5%), injection-site erythema (4–5%), upper respiratory infections (3–4%) and urinary tract infections (3%). The manufacturer claims that the U.S. Wholesale Acquisition Cost (WAC) of sarilumab is $39,000/year for the 200 mg and 150 mg doses, which is approximately 30% lower than the WAC price for the two most commonly used TNF-alpha inhibitors.

You Might Also Like
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
  • 2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
  • FDA Approves Updated Labeling on Risk of Osteonecrosis of the Jaw for Denosumab
Also By This Author
  • Updated EULAR Recommendations for Early Arthritis; Plus FDA Approves New Abuse-Deterrent Morphine Sulfate

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products—diclofenac sodium 2% topical solution. 2017 May 15.
  2. U.S. Food and Drug Administration. Drugs@FDA: FDA approved drug products—Pennsaid (diclofenac sodium 2% topical solution). 2014 Jan 16.
  3. Kocjan T, Rajic AS, Sever MJ et al. The effect of denosumab or bisphosphonates in women with severe postmenopausal osteoporosis after completion of teriparatide treatment. Endocrine Abstracts. 2017:49[abstract OC10.4] DOI: 10.1530/endoabs.49.OC10.4
  4. Berrie C. Denosumab more effective than bisphosphonates in treating severe, post-menopausal osteoporosis post-teriparatide: Presented At ECE. First Word: Pharma. 2017 May 26.
  5. Regeneron Pharmaceuticals Inc. Regeneron and Sanofi announce FDA approval of Kevzara (sarilumab) for the treatment of moderately to severely active rheumatoid arthritis in adult patients. 2017 May 22.

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: denosumab, diclofenac sodium, FDA, Food and Drug Administration, generic drugs, Knee Osteoarthritis (OA), Osteoporosis, Rheumatoid Arthritis (RA), sarilumab

You Might Also Like:
  • Rheumatology Drug Updates: Biosimilars Receive Positive News & More
  • 2014 ACR/ARHP Annual Meeting: Rheumatology Drug Updates, Safety News
  • FDA Approves Updated Labeling on Risk of Osteonecrosis of the Jaw for Denosumab
  • Sarilumab Approval Stalled; Piclidenoson Promising for Psoriasis

Patient & Caregiver Resources

Find a rheumatology provider. Learn about your condition and how to live with it. English and Spanish language resources.

View Patient & Caregiver Resources »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)